



Hypofractionated Radiotherapy Versus Conventional Radiotherapy in Management of Patients with High Grade Gliomas Older Patients and Poor Performance State

Thesis

*Submitted for Partial Fulfillment of the M.D. Degree in
Clinical Oncology and Nuclear Medicine*

Presented by

Mariam Mohamed Hussien

M.B, B. Ch.; M.Sc

Faculty of medicine – Ain Shams University

Supervised By

Prof. Dr. Hesham Ahmed Elghazaly

Professor of Clinical Oncology and Nuclear Medicine

Faculty of Science – Ain Shams University

Ass. Prof. Dr. Dina Ahmed Salem

Assistant Professor of Clinical Oncology and Nuclear Medicine

Faculty of medicine – Ain Shams University

Ass. Prof. Dr. Nagi Sami Gobran

Assistant Professor of Clinical Oncology and Nuclear Medicine

Faculty of medicine – Ain Shams University

*Faculty of Medicine
Ain Shams University*

2017

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سبحانك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Hesham Ahmed Elghazaly**, Professor of Clinical Oncology and Nuclear Medicine Faculty of Science – Ain Shams University for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Ass. Prof. Dr. Dina Ahmed Salem**, Assistant Professor of Clinical Oncology and Nuclear Medicine Faculty of medicine – Ain Shams University, for her kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I am deeply thankful to **Ass. Prof. Dr. Magi Sami Gobran**, Assistant Professor of Clinical Oncology and Nuclear Medicine Faculty of medicine – Ain Shams University, for his great help, active participation and guidance.*

Mariam Mohamed Hussien

List of Contents

| Title | Page No. |
|---|----------|
| List of Tables | 1 |
| List of Figures | 2 |
| List of Abbreviations | 5 |
| Abstract | viii |
| Introduction | 1 |
| Aim of the Work..... | 14 |
| Review of Literature | |
| 1- Epidemiology of High Grade Glioma..... | 15 |
| 2- Clinical Picture | 23 |
| 3- Treatment..... | 33 |
| Patient and Methods | 80 |
| Results | 87 |
| Discussion | 104 |
| Summary and Recommendation..... | 110 |
| References | 114 |
| Arabic Sumamry | |

List of Tables

| Table No. | Title | Page No. |
|--------------------|---|----------|
| Table (1): | Karnosky Performance Scale..... | 35 |
| Table (2): | Guidelines for target delineation of glioblastoma, according to the European Organization for Research and Treatment of Cancer (EORTC) and the Radiation Therapy Oncology Group (RTOG): | 49 |
| Table (3): | OAR definitions and dose limits in GBM patients - individual adaptation necessary according to the clinical situation..... | 64 |
| Table (4): | Macdoland response response criteria..... | 79 |
| Table (5): | Showed (OAR) and dose limitation:..... | 83 |
| Table (6): | Summarizes the 50 patients' characteristics in regards to their age, gender, karnofsky scale, clinical presentation, site of tumor, surgery, pathology type, steroid at start and steroid dependence..... | 87 |
| Table (7): | Response rate assessed by MRI brain. | 89 |
| Table (8): | Showed Progression free survival between group I and group II..... | 91 |
| Table (9): | Showed Overall survival between group I and group II. | 92 |
| Table (10): | Showed Overall survival between group I and group II in age ≥ 60 -69 years..... | 93 |
| Table (11): | Showed Overall survival between group I and group II in age ≥ 70 years. | 94 |
| Table (12): | Showed Overall survival relation between all parameters in group I (conventional)..... | 95 |
| Table (13): | Overall survival relation between all parameters in group II (hypofractionation)..... | 99 |
| Table (14): | Shows Comparison between groups according to completion of Rth and steroid dependence..... | 102 |
| Table (15): | Comparison between groups according to acute toxicity..... | 103 |

List of Figures

| Fig. No. | Title | Page No. |
|---------------------|--|----------|
| Figure (1): | Infographic of the brain | 23 |
| Figure (2): | Magnetic resonance imaging (MRI) of a typical case of glioblastoma..... | 25 |
| Figure (3): | On MR spectroscopy, there is decrease in NAA levels with increase in Cho/Cr ratio in the lesion suggest high grade glioma..... | 27 |
| Figure (4): | Heterogenous intra-axial mass in right parietal region, the rim enhancement corresponds well with the areas of high perfusion on rCBV..... | 29 |
| Figure (5): | Intraoperative software (upper right) showing a 3D rendering of the patient with three of the four..... | 40 |
| Figure (6): | Left frontal lobe glioblastoma (subsequently delineated in CT/CE T1/FLAIR slices), GTV (purple) | 66 |
| Figure (7): | Case of left tempoparietal Glioblastoma (postoperative).for hypofractionation.GTV in red, CTV in yellow, PTV in blue..... | 82 |
| Figure (8): | Color wash of 95% of the dose coverage of PTV for patient with LT tempoparietal GBM. | 84 |
| Figure (9): | Showed a comparison between two groups according radiological response rate..... | 89 |
| Figure (10): | Showed MRI for patient with LT tempoparietal glioblastoma multiform pre-radiotherapy..... | 90 |
| Figure (11): | Follow up in the same patient by MRI brain with contrast 6 weeks after hypofractionation radiotherapy showed complete response. | 90 |

List of Figures cont...

| Fig. No. | Title | Page No. |
|---------------------|--|----------|
| Figure (12): | Progression free survival between group I and group II is shown. | 91 |
| Figure (13): | Overall survival between group I and group II is shown. | 92 |
| Figure (14): | Overall survival between group I and group II is shown in age ≥ 60 -69 years. | 93 |
| Figure (15): | Overall survival between group I and group II is shown in age ≥ 70 years. | 94 |
| Figure (16): | Showed statistically significant overall survival difference between different age group. | 96 |
| Figure (17): | Patient's performance KFS (60-70) have statistically survival benefit than those KFS 50 with P value 0.009. | 96 |
| Figure (18): | Patients without seizures at presentation showed statistically significant overall survival than patient presented by seizure P value < 0.001 | 97 |
| Figure (19): | Maximum safe resection is associated with statistically significant overall survival with P = 0.049. | 97 |
| Figure (20): | Patients who were not steroid dependent median survival was 9 month while those who were steroid dependent median was 6 month | 98 |
| Figure (21): | Overall survival was significant better in patients with KFS 70 with P value < 0.001 | 100 |
| Figure (22): | Overall survival according to tumor site is shown in group II showed significance survival benefit for LT temporoparietal site P = 0.007. | 100 |

List of Figures cont...

| Fig. No. | Title | Page No. |
|---------------------|--|----------|
| Figure (23): | Overall survival in steroid dependant patient was 6.8 month while 8.9 month in non dependant patients with P value <0.001..... | 101 |
| Figure (24): | Bar chart between groups according to finish Rth and steroid dependency..... | 102 |
| Figure (25): | Bar chart between groups according to acute toxicity. | 103 |

List of Abbreviations

| Abb. | Full term |
|---------------------|---|
| <i>5-ALA</i> | <i>5-aminolevulinic acid</i> |
| <i>AA</i> | <i>Anaplastic astrocytomas</i> |
| <i>ADC</i> | <i>Apparent diffusion coefficient</i> |
| <i>AEDs</i> | <i>Antiepileptic drugs</i> |
| <i>ASCO</i> | <i>American Society of Clinical Oncology Clinical</i> |
| <i>ATRX</i> | <i>A thalassemia/mental retardation syndrome</i> <i>X-linked</i> |
| <i>BED</i> | <i>Biological effective dose</i> |
| <i>BTCCG</i> | <i>Brain Tumor Cooperative Group</i> |
| <i>BTV</i> | <i>Biological tumor volume</i> |
| <i>CBTRUS</i> | <i>Central Brain Tumor Registry of the United</i> <i>States</i> |
| <i>CBV</i> | <i>Cerebral blood volume</i> |
| <i>CDK</i> | <i>cyclin-dependent kinase</i> |
| <i>CR</i> | <i>Complete response</i> |
| <i>CRT</i> | <i>Chemoradiotherapy</i> |
| <i>CT</i> | <i>Computer tomography</i> |
| <i>CTV</i> | <i>Clinical target volumes</i> |
| <i>DSC</i> | <i>Dynamic susceptibility weighted contrast-</i> <i>enhanced</i> |
| <i>DWI</i> | <i>Diffusion Weighted Imaging</i> |
| <i>EGFR</i> | <i>Epidermal growth factor receptor</i> |
| <i>EORTC</i> | <i>European Organization for Research and</i> <i>Treatment of Cancer</i> |
| <i>FDG</i> | <i>18-fluorodeoxyglucose</i> |
| <i>FGF</i> | <i>Fibroblast growth factor</i> |
| <i>FSRT</i> | <i>Fractionated stereotactic radiotherapy</i> |
| <i>GBM</i> | <i>Glioblastoma multiforme</i> |
| <i>G-CIMP</i> | <i>Glioma-CpG island methylator phenotype</i> |
| <i>GRT</i> | <i>Gross total resection</i> |

List of Abbreviations cont...

| Abb. | Full term |
|-----------------------|---|
| <i>GTV</i> | <i>Gross tumor volume</i> |
| <i>HFRT</i> | <i>Hypofractionated radiotherapy</i> |
| <i>HGGs</i> | <i>High-grade gliomas</i> |
| <i>HRQOL</i> | <i>Health-related quality of life</i> |
| <i>hTERT</i> | <i>High frequency of telomerase reverse transcriptase</i> |
| <i>IARC</i> | <i>International Agency for Research on Cancer</i> |
| <i>IDH</i> | <i>Isocitrate dehydrogenase</i> |
| <i>IDH1/2</i> | <i>Isocitrate dehydrogenase enzyme ½</i> |
| <i>IFRT 125</i> | <i>I implants following standard</i> |
| <i>iMRI</i> | <i>Intraoperative MRI</i> |
| <i>IMRT</i> | <i>Intensity modulated RT</i> |
| <i>KPS</i> | <i>Karnofsky Performance Status</i> |
| <i>LOH</i> | <i>Loss of heterozygosity</i> |
| <i>LQ</i> | <i>Linear-quadratic</i> |
| <i>MDM2</i> | <i>Mouse double-minute 2</i> |
| <i>MGMT</i> | <i>O6-methylguanine-DNA methyltransferase (),</i> |
| <i>MRI</i> | <i>Magnetic resonance imaging</i> |
| <i>MRS</i> | <i>MR Spectroscopy</i> |
| <i>MS</i> | <i>Median survival</i> |
| <i>MVA</i> | <i>Microvascular density or area</i> |
| <i>NABTT</i> | <i>New Approaches to Brain Tumor Therapy</i> |
| <i>OARs</i> | <i>Organs at risk</i> |
| <i>OS</i> | <i>Overall survival</i> |
| <i>PBI</i> | <i>Partial brain irradiation</i> |
| <i>PD</i> | <i>Progressive disease</i> |
| <i>PDGF</i> | <i>Platelet-derived growth factor</i> |
| <i>PET</i> | <i>Positron emission tomography</i> |
| <i>PFS</i> | <i>Progression free survival</i> |

List of Abbreviations cont...

| Abb. | Full term |
|----------------------|--|
| <i>PR</i> | <i>Partial response</i> |
| <i>PRV</i> | <i>Planning risk volume</i> |
| <i>PTEN</i> | <i>Phosphatase and tensin homologue</i> |
| <i>PTV</i> | <i>Planning target volume</i> |
| <i>rCBV</i> | <i>Relative cerebral blood volume</i> |
| <i>RCx/TMZ</i> | <i>Receive concomitant chemoradiotherapy and adjuvant temozolimide</i> |
| <i>RPA</i> | <i>Recursive partitioning analysis</i> |
| <i>RT</i> | <i>Radiation therapy</i> |
| <i>RTOG</i> | <i>RT Oncology Group</i> |
| <i>SD</i> | <i>Stable disease</i> |
| <i>SEER</i> | <i>Surveillance, epidemiology and end results</i> |
| <i>STR</i> | <i>Subtotal resection</i> |
| <i>TAC</i> | <i>Time activity curve</i> |
| <i>TERT</i> | <i>Telomerase reverse transcriptase</i> |
| <i>TMZ</i> | <i>Temozolimide</i> |
| <i>TP53</i> | <i>Tumor protein</i> |
| <i>UK MRC</i> | <i>United Kingdom Molecular Research Council</i> |
| <i>VEGF</i> | <i>Vascular endothelial growth factor</i> |
| <i>VMAT</i> | <i>Volumetric modulated arc therapy</i> |
| <i>WBRT</i> | <i>Whole-brain radiotherapy</i> |

Abstract

In our study steroid dependency (failure to taper steroid after radiotherapy) was a predictor for poor survival in both conventional and hypofractionated arm and with statistically significant difference on those patients nondependent on steroids.

In our study (clinical symptoms at presentation) in each arm failed to correlate to survival except the seizure which was significant associated with lower survival in conventional arm only. Finally, our study failed to identify tumor size as prognostic factor for GBM.

Our recommendations is to adopt short hypofractionated radiotherapy in management of elderly and poor performance patients with high grade glioma as the hypofractionated conformal radiotherapy was found to be as effective as the conventional radiotherapy with no severe adverse effects. Especially in patients over 70 years old in whom survival was statistically significant better than with conventional arm.

Considering the benefit of the short-course regimen in terms of time sparing for patients, and for radiation oncology centers, which are often overloaded by long patient waiting lists, the hypofractionated radiotherapy should be evaluated among younger and good performance patients.

Studies with greater number of patients are advised to realistic evaluation of glioblastoma prognostic factors. And we recommend further study about hypofractionated radiotherapy with temozolomide.

Keywords: Glioblastoma multiforme - Hypofractionated radiotherapy- Karnofsky Performance Status- Overall survival

INTRODUCTION

Malignant gliomas, including glioblastoma multiforme (GBM) are the most common primary brain tumors in adults and the age adjusted incidence of these high-grade gliomas has increased over recent years. The incidence annually is 2 to 3 per 100,000 people in the United States and Europe. GBM accounts for 12% to 15% of all intracranial tumors and 50% to 60% of astrocytic tumors (*Kohler et al., 2011*).

Epidemiological data on CNS tumors as they occur in Egypt have been rather incomplete although there are some regional reports. In an epidemiological study done in the Egyptian National Cancer Institute, CNS neoplasms constitute about 3% of primary malignant tumors (*EL-Bolkainy, 1998*).

A study was done to estimate the frequency of CNS tumors in east delta region, Egypt. In which the data were collected during the 8-year period from January 1999 to December 2007 from Pathology Department, Mansoura University, and other referred pathology labs. The study showed that: Intracranial tumors represented 86.7% of cases in comparison to only 13.3% for spinal tumors. Gliomas were the CNS tumors of the highest frequency (35.2%) (*Zalata et al., 2011*).

The risk stratification scheme utilizing Radiation Therapy Oncology Group Recursive Partitioning Analysis of Malignant Glioma (RPA) has been used to categorize patients

with anaplastic astrocytoma or glioblastoma into different prognostic groups. The age was the most important predictor of survival, with patients <50 years faring better than older patients. Karnofsky performance status (KPS >70 more favorable than <70) was the next most significant prognostic factor in patients with malignant glioma. risk factors also include extent of resection, and neurologic function at the time of presentation (*Siker et al., 2011*).

The combination of surgery, radiation therapy, and chemotherapy represents the standard approach to the treatment of malignant gliomas. Generally, surgery is performed through an open craniotomy. The goals of surgery are to provide a histologic diagnosis, to alleviate intracranial hypertension and focal neurologic deficits resulting from a mass effect, and to permit rapid corticosteroid dose tapering. The influence of surgical resection in malignant gliomas has been controversial. The aim of palliation of symptoms was always clear, but the survival advantage was debated (*Pang et al., 2007*).

The benefits of postoperative radiation therapy for glioblastoma was first proven in the Brain Tumor Study Group randomized trial in the 1970s. Median survival was increased to 37.5 weeks from 17 weeks when postoperative radiotherapy was given compared with best supportive care alone. Subsequent dose response studies have established 60 Gy delivered in 1.8- to 2.0-Gy fractions as the best treatment regimen. In 2005, after the publication of the results of a

European Organisation for Research and Treatment of Cancer (EORTC)/National Cancer Institute of Canada phase III randomized trial comparing postoperative radiotherapy and postoperative radiotherapy with concurrent and adjuvant temozolomide, the latter was established as the standard of care because it showed statistically significant survival benefit ($p<0.001$) (*Stupp et al., 2005*).

The use of conventional RT schemes (60–66 Gy in 30–33 fractions) often requires 6–7 weeks. This long period of treatment affects patient psycho-sociologically and reduces the quality of life while increasing cost. Shortening the treatment and controlling the symptoms of these patients are important considerations. Numerous studies have found that shorter course of RT might be an appropriate option for the patients with high grade gliomas, especially those who have poor prognosis (*Meral et al., 2007*).

the United Kingdom Molecular Research Council (UK MRC), and European Organization for Research and Treatment of Cancer (EORTC) prognostic groups have consistently shown that elderly patients and those with poor performance do poorly. Shortened treatment time may be advantageous for many elderly patients as it potentially maximizes out-of-hospital time in this disease with limited prognosis (*Scott et al., 2012*).

In a retrospective study from the University of Texas M. D. Anderson Cancer Center, 59 patients with glioblastoma who were